







WHAT IS CLAIMED IS:

1. A compound selected from:


,

,

, and

,

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 selected from:


,

,

, and

, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:


1-{4-[(4-{[(3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-3-hydroxypiperidin-1-yl]carbonyl}-5-fluoropyridin-2-yl)amino]piperidin-1-yl}ethanone,

(6-(2,2-difluorocyclopropyl)imidazo[1,2-a]pyrimidin-2-yl)((3S,4S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-3-hydroxypiperidin-1-yl)methanone,

(6-cyclopropylimidazo[1,2-a]pyrimidin-2-yl)((3S,4S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-3-hydroxypiperidin-1-yl)methanone, or


(6-bromo-7-ethylimidazo[1,2-a]pyrimidin-2-yl)((3S,4S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-3-hydroxypiperidin-1-yl)methanone.

4. A compound of claim 1, which is:




, or a pharmaceutically acceptable salt thereof.

5. A compound of claim 1, which is:




, or a pharmaceutically acceptable salt thereof.

6. A compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.

7. A compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, which is: 1-{4-[(4-{[(3*S*,4*S*)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-3-hydroxypiperidin-1-yl]carbonyl}-5-fluoropyridin-2-yl)amino]piperidin-1-yl}ethenone. or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, which is: (6-(2,2-difluorocyclopropyl)imidazo[1,2-a]pyrimidin-2-yl)((3S,4S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-3-hydroxypiperidin-1-yl)methanone, or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, which is: (6-cyclopropylimidazo[1,2-a]pyrimidin-2-yl)((3S,4S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-3-hydroxypiperidin-1-yl)methanone, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, which is: (6-bromo-7-ethylimidazo[1,2-a]pyrimidin-2-yl)((3S,4S)-4-(3,4-dihydroisoquinolin-2(1H)-yl)-3-hydroxypiperidin-1-yl)methanone, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising a compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, for treating cancer.

~~14. The method for treating cancer comprising administering to a patient in need thereof a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof.~~

~~15.~~14. The use of ~~method for treating sickle cell disease comprising administering to a patient in need thereof~~ a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating sickle cell disease.

~~16.~~15. The use of ~~method for treating hereditary persistence of foetal hemoglobin (HPFH) mutations comprising administering to a patient in need thereof~~ a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating hereditary persistence of foetal hemoglobin (HPFH) mutations.

~~17.~~16. The use of a compound of any of claims 1-11, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer.